FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein. Note=Defects in MET may be associated with gastric cancer. Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550]. Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes. Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. Contains 3 IPT/TIG domains. Contains 1 protein kinase domain. Contains 1 Sema domain.
DomainThe kinase domain is involved in SPSB1 binding.
Post-translational modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab68141 at a dilution of 1/50.
Western blot - Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)
All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/5000 dilution
Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h. Whole cell lysates Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates. Then the membrane was incubated with phosphatase.
Lysates/proteins at 15 µg per lane.
Secondary Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Dot Blot - Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)
Dot blot analysis of Met (c-Met) (phospho Y1349) phospho peptide (Lane 1), Met (c-Met) Non-phospho peptide (Lane 2), labelling Met (c-Met) (phospho Y1349) with ab68141 at a dilution of 1/1000. Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/2500.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
References for Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)
This product has been referenced in:
Majumder B et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun6:6169 (2015).
Read more (PubMed: 25721094) »
Gerdes MJ et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A110:11982-7 (2013).
Read more (PubMed: 23818604) »